Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDPraxis Precision Medicines, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 7 | -$3.42 | -$2.46 | -$3.20 |
| Q2 2025 | 3 | -$3.17 | -$3.17 | -$3.17 |
| Q3 2025 | 3 | -$3.08 | -$3.08 | -$3.08 |
| Q4 2025 | 6 | -$2.95 | -$2.95 | -$2.95 |
| Q1 2026 | 5 | -$3.37 | -$3.37 | -$3.37 |
| Q2 2026 | 4 | -$3.59 | -$3.59 | -$3.59 |
| Q3 2026 | 3 | -$3.52 | -$3.52 | -$3.52 |
| Q4 2026 | 2 | -$3.26 | -$3.26 | -$3.26 |
| Q1 2027 | 2 | $0.00 | $0.00 | $0.00 |
| Q2 2027 | 2 | $0.00 | $0.00 | $0.00 |
| Q3 2027 | 2 | $0.00 | $0.00 | $0.00 |
| Q4 2027 | 2 | $0.00 | $0.00 | $0.00 |
Praxis Precision Medicines, Inc. Earnings Date And Information
Praxis Precision Medicines, Inc. last posted its earnings results on Friday, February 28th, 2025. The company reported $-2.94 earnings per share for the quarter, missing analysts' consensus estimates of $-2.76 by $0.18. The company had revenue of 7.46 M for the quarter and had revenue of 8.55 M for the year. Praxis Precision Medicines, Inc. has generated $-10 earnings per share over the last year ($-10.21 diluted earnings per share) and currently has a price-to-earnings ratio of -4.22. Praxis Precision Medicines, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based on prior year's report dates.
Praxis Precision Medicines, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/28/2025 | Q4 2024 | -$2.76 | -$2.94 | -0.18 | $398,475 | $7.46 M |
| 11/06/2024 | Q3 2024 | -$2.01 | -$2.75 | -0.74 | $328,556 | $302,000 |
| 08/13/2024 | Q2 2024 | -$2.38 | -$1.74 | 0.64 | $931,222 | $357,000 |
| 05/13/2024 | Q1 2024 | -$2.01 | -$2.84 | -0.83 | N/A | $431,000 |
| 03/05/2024 | Q4 2023 | -$3.15 | -$2.97 | 0.18 | $300,000 | $515,000 |
| 11/07/2023 | Q3 2023 | -$5.25 | -$2.72 | 2.53 | N/A | $468,000 |
| 08/09/2023 | Q2 2023 | -$9.90 | -$7.38 | 2.52 | N/A | $781,000 |
| 05/11/2023 | Q1 2023 | -$11.24 | -$10.40 | 0.84 | N/A | $683,000 |
| 02/07/2023 | Q4 2022 | -$10.94 | -$12.89 | -1.95 | N/A | $0 |
| 11/09/2022 | Q3 2022 | -$13.79 | -$14.29 | -0.5 | N/A | $0 |
| 08/08/2022 | Q2 2022 | -$19.49 | -$19.76 | -0.27 | N/A | $0 |
| 05/09/2022 | Q1 2022 | -$19.34 | -$22.63 | -3.29 | N/A | $0 |
| 02/28/2022 | Q4 2021 | -$16.19 | -$19.54 | -3.35 | N/A | $0 |
| 11/03/2021 | Q3 2021 | -$13.94 | -$15.00 | -1.06 | N/A | $0 |
| 08/16/2021 | Q2 2021 | -$10.19 | -$13.13 | -2.94 | N/A | $0 |
| 05/11/2021 | Q1 2021 | -$11.09 | -$10.67 | 0.42 | N/A | $0 |
| 03/17/2021 | Q4 2020 | -$5.70 | -$12.56 | -6.86 | N/A | $0 |
| 11/23/2020 | Q3 2020 | -$0.73 | -$146.01 | -145.28 | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$105.64 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$76.69 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Praxis Precision Medicines, Inc. Earnings: FAQ's
Praxis Precision Medicines, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based offlast year's report dates.
The conference call for Praxis Precision Medicines, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Praxis Precision Medicines, Inc.'s latest earnings report can be read online.
Praxis Precision Medicines, Inc. (:PRAX) has a recorded annual revenue of $8.55 M.
Praxis Precision Medicines, Inc. (:PRAX) has a recorded net income of $-182,819,000.Praxis Precision Medicines, Inc. has generated $-10.21 earnings per share over the last four quarters.
Praxis Precision Medicines, Inc. (:PRAX) has a price-to-earnings ratio of -4.22 and price/earnings-to-growth ratio is -14.47.